中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

丙型肝炎病毒实验性疫苗免疫学评价

管洁 谭文杰

管洁, 谭文杰. 丙型肝炎病毒实验性疫苗免疫学评价[J]. 临床肝胆病杂志, 2011, 27(1): 23-27.
引用本文: 管洁, 谭文杰. 丙型肝炎病毒实验性疫苗免疫学评价[J]. 临床肝胆病杂志, 2011, 27(1): 23-27.
Guan Jie, Tan WenJie. The immunological evaluation of hepatitis C virus vaccine[J]. J Clin Hepatol, 2011, 27(1): 23-27.
Citation: Guan Jie, Tan WenJie. The immunological evaluation of hepatitis C virus vaccine[J]. J Clin Hepatol, 2011, 27(1): 23-27.

丙型肝炎病毒实验性疫苗免疫学评价

详细信息
  • 中图分类号: R392

The immunological evaluation of hepatitis C virus vaccine

  • 摘要:

    丙型肝炎病毒(HCV)属于黄病毒科,其基因组为单股正链RNA,易变异,慢性感染可导致肝脏慢性炎症坏死和纤维化,部分患者可发展为肝硬化甚至肝细胞癌,对患者的健康和生命危害极大,已成为严重的社会和公共卫生问题,目前尚无有效的疫苗。本文综述了HCV实验性疫苗的免疫学评价方法,为疫苗的研制及应用提供参考。

     

  • [1]Lindenbach B, Rice C.Unraveling hepatitis C virus replication from genome to function[J].Nature, 2005, 436 (7053) :933-938.
    [2]Lavanchy D, Purcell R, Hollinger FB, et al.Global surveillance and control of hepatitis C[J].Viral Hepat, 1999, 6 (1) :35-47.
    [3]De Francesco R, Migliaccio G.Challenges and succ-esses in developing new therapies for hepatitis C[J].Nature, 2005, 436 (7053) :953-960.
    [4]Lauer GM, Walker BD.Hepatitis C Virus Infection[J].N Engl J Med, 2001, 345 (1) :41-52.
    [5]Thimme R, Oldach D, Chang KM, et al.Determinants of viral clearance and persistence during acute hepatitis C virus infection[J].Exp Med, 2001, 194 (10) :1395-1406.
    [6]Cooper S, Erickson AL, Adams EJ, et al.Analysis of a successful immune response against hepatitis C virus[J].Immunity, 1999, 10 (4) :439-449.
    [7]Lechner F, Wong D, Dunbar P, et al.Analysis of successful immune responses in persons infected with hepatitis C virus[J].J Exp Med, 2000, 191 (9) :1499-1512.
    [8]Cox A, Mosbruger T, Lauer G, et al.Comprehensive analyses of CD8+T cell responses during longitudinal study of acute human hepatitis C[J].Hepatology, 2005, 42 (1) :104-112.
    [9]Lechner, F.Gruener N, Urbani S, et al.CD8+T lymphocyte responses are included during acute hepatitis C rirus infection but are not sustained[J].Eur J Immunol, 2000, 30 (9) :2 479-2487.
    [10]Bassett S, Guerra B, Brasky K, et al.Protective im-mune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection[J].Hepatology, 2001, 33 (6) :1479-1487.
    [11]Lanford, R, Guerra B, Chavez D, et al.Cross-genotype immunity to hepatitis C virus[J].J Virol, 2004, 78 (3) :1575-1581.
    [12]Thimme R, Oldach D, Chang K, et al.Determinants of viral clearance and persistence during acute hepatitis C virus infection[J].J Exp Med, 2001, 194 (10) :1395-1406.
    [13]Shoukry N, Cawthon A, Walker C.Cell-mediated im-munity and the outcome of hepatitis C virus infection[J].Annu Rev Microbiol, 2004, 58:391-424
    [14]Ulsenheimer A, Gerlach J, Gruener N, et al.Detection of functionally altered hepatitis C virus-specific CD4+T cells in acute and chronic hepatitis C[J].Hepatology, 2003, 37 (5) :1189-1198
    [15]Wedemeyer H, He X, Nascimbeni M, et al.Impaired effector function of hepatitis C virus-speci-c CD8+T cells in chronic hepatitis C virus Infection[J].J Immunol, 2002, 169 (6) :3447-3458.
    [16]Appay V, Dunbar P, Callan M, et al.Memory CD8+T cells vary in differentiation phenotype in different persistent virus infections[J].Nat Med, 2002, 8 (4) :379-385.
    [17]Choo Q, Kuo G, Ralston R, et al.Vaccination of chi-mpanzees against infection by the hepatitis C virus[J].Proc Natl Acad Sci, 1994, 91 (4) :1294-1298.
    [18]Farci P, Shimoda A, Wong D, et al.Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein[J].Proc Natl Acad Sci, 1996, 93 (26) :15394-15399.
    [19]Grakoui A, Shoukry N, Woollard D, et al.HCV persistence and immune evasion in the absence of memory T cell help[J].Science, 2003, 302 (5645) :659-662.
    [20]Thimme R, Bukh J, Spangenberg H, et al.Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease[J].Proc Natl Acad Sci, 2002, 99 (24) :15661-15668.
    [21]Folgori A, Capone S, Ruggeri L, et al.A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees[J].Nat Med, 2006, 12 (2) :190-197.
    [22]Grakoui A, Shoukry NH, Woollard DJ, et al.HCV persistence and immune evasion in the absence of memory T cell help[J].Science, 2003, 302 (5645) :659-662.
    [23]Neumann C, Thimme R.Impact of the genetic restriction of virus-specific T-cell responses in hepatitis C virus infection[J].Genes Immun, 2007, 8 (3) :181-192.
    [24]Houghton M, Abrignani S.Prospects for a vaccine against the hepatitis C virus[J].Nature, 2005, 436 (7053) :961-966.
    [25]Rosa D, Campagnoli S, Moretto C, et al.A quantitative test to estimate neutralizing antibodies to the hepatitis C virus:cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells[J].Proc Natl Acad Sci, 1996, 93 (5) :1759-1763.
    [26]Bartosch B, Dubuisson J, Cosset F.Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1-E2 Envelope Protein Complexes[J].J Exp Med, 2003, 197 (5) :633-642.
    [27]Wakita T, Pietschmann T, Kato T, et al.Production of临床肝胆病杂志2011年第27卷第1期infectious hepatitis C virus in tissue culture from a cloned viral genome[J].Nat Med, 2005, 11 (7) :791-796.
    [28]Lindenbach B, Evans M, Syder A, et al.Complete replication of hepatitis C virus in cell culture[J].Science, 2005, 309 (5734) :623-626.
    [29]Stamataki Z, Coates S, Evans M, et al.Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies[J].Vaccine, 2007, 25 (45) :7773-7784.
    [30]Kreher C, Dittrich M, Guerkov R, et al.CD4+and CD8+cells in cryopreserved human PBMC maintain full functionality in cytokine C virus in cell culture[J].Science, 2005, 309 (5734) :623-626.
    [31]Diepolder H, Zachoval R, Hoffmann R, et al.Possible mechanism involving T lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection[J].Lancet, 1995, 346 (8981) :1 006-1007.
    [32]Rigopoulou E, Suri D, Chokshi S, et al.Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B:antiviral and immunological activity[J].Hepatology, 2005, 42 (5) :1028-1036.
    [33]Elmowalid G, Qiao M, Jeong S, et al.Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees[J].Proc Natl Acad Sci, 2007, 104 (20) :8427-8432.
    [34]Murata K, Lechmann M, Ming Q, et al.Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection[J].Proc Natl Acad Sci, 2003, 100 (11) :6753-6758
    [35]Simon B, Cornell K, Clark T, et al.DNA Vaccination Protects Mice against Challenge with Listeria monocytogenes Expressing the Hepatitis C Virus NS3 Protein[J].Infect Immun, 2003, 71 (11) :6372-6380.
    [36]Encke J, Findeklee J, Geib J, et al.Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection[J].Clin Exp Immunol, 2005, 142 (2) :362-369.
  • 加载中
计量
  • 文章访问数:  4244
  • HTML全文浏览量:  11
  • PDF下载量:  1045
  • 被引次数: 0
出版历程
  • 出版日期:  2011-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回